Non-GCB/ABC Diffuse Large B-Cell Lymphoma, With and Without MyD88 and/or CD79B Mutations
Conditions
Keywords
Mivavotinib, DLBCL, MyD88, CD79b, non-GCB, ABC, NHL, CB-659, Relapsed/Refractory
Brief summary
Study CX-659-401 is a multicenter, open-label, phase 2 study of mivavotinib to evaluate the single-agent activity of mivavotinib in patients with relapsed/refractory non-GCB/ABC DLBCL, incorporating ctDNA-based next-generation sequencing (NGS) to identify DLBCL patients harboring MyD88 and/or CD79B mutations within the study. This goal of this strategy is to evaluate its activity both in the cell-of-origin subgroup of non-GCB/ABC DLBCL and in the genetically defined subgroups of MyD88/CD79B-mutated and wild type DLBCL.
Detailed description
Approximately 50 patients will be randomized 1:1 to one of two dose/schedule cohorts: one with a continuous dosing schedule (100 mg QD) and one with an induction dosing schedule (120 mg QD x 14 days, then 80 mg QD starting Day 15). Patients will receive treatment with mivavotinib until disease progression, unacceptable toxicity, withdrawal of consent, or death.
Interventions
DRUGMivavotinib
oral tablet
Sponsors
Calithera Biosciences, Inc
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No
Inclusion criteria
1. Male or female patients aged 18 years or older 2. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2 3. Life expectancy of \> 3 months 4. Histologically confirmed de novo or transformed non-GCB DLBCL. 5. Relapsed or refractory to ≥ 2 prior lines of chemotherapy based on standard of care 6. Patients should not have failed more than 5 prior lines of therapy 7. Must have \[18F\]Fluorodeoxyglucose-positron emission tomography (FDG-PET)-avid measurable disease that meets the size criteria per International Working Group (IWG) criteria. 8. Must have recovered from adverse events of prior anti-cancer therapy to severity ≤ Grade 1. 9. Adequate organ function as assessed by laboratory values. 10. If female of childbearing potential, agreement to use protocol specified contraception methods. If male, agreement to use an effective barrier method of contraception.
Exclusion criteria
1. DLBCL with central nervous system (CNS) involvement with active brain or leptomeningeal disease 2. Known human immunodeficiency (HIV; testing not required) or HIV-related malignancy 3. Known hepatitis B surface antigen positive or known or active hepatitis C infection 4. Prior autologous stem cell transplant (ASCT) or chimeric antigen receptor T-cell (CAR-T) cell infusion within 90 days of screening 5. Prior allogeneic stem cell transplantation 6. Unstable/inadequate cardiac function 7. Known gastrointestinal (GI) disease or GI procedure that interferes with swallowing/absorption of oral drug 8. Major surgery within 14 days before the first dose of study drug 9. Serious infection (bacterial/fungal/viral) requiring parenteral antibiotic/antiviral therapy for \>5 days within 21 days prior to first dose of study drug 10. Treatment with high-dose corticosteroids for anticancer purposes within 7 days before the first dose of mivavotinib. 11. Use of medication known to be inhibitors or inducers of P-glycoprotein (P-gp) and/or Cytochrome P (CYP)3A 12. Female patients who are pregnant, lactating or breastfeeding. 13. Any radiation therapy within 3 weeks prior to first dose of study treatment. 14. Systemic anticancer treatment within 3 weeks before first dose of study treatment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Response Rate (ORR) as assessed by an independent radiology review committee (IRC) according to the 2014 International Working Group (IWG) Lugano Criteria (Cheson, 2014). | Start of treatment up to 21 months | Overall response is defined as a complete response (CR) or partial response (PR). ORR is the proportion of participants who have overall responses. |
| Safety as measured by type, incidence, severity, seriousness, and study drug-relatedness of adverse events per Common Terminology Criteria for Adverse Events, version 5 | Start of treatment up to 21 months | Type, incidence, severity, seriousness, and study drug-relatedness of AEs assessed by CTCAE v5.0 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Duration of Response (DOR) Rate as assessed by an IRC according to the 2014 International Working Group (IWG) Lugano Criteria (Cheson, 2014). | Start of treatment up to 21 months | DOR per IRC. DOR will be calculated as the time between the first documentation of partial response (PR) or a complete response (CR) to the first documentation of progressive disease or death, whichever occurs first. |
| Progression-Free Survival (PFS) as assessed by an IRC according to the 2014 International Working Group (IWG) Lugano Criteria (Cheson, 2014). | Start of treatment up to 21 months | PFS per IRC. PFS is defined as the time from randomization to the first occurrence of disease progression as determined by the IRC or death from any cause, whichever occurs first. |
| Complete Response (CR) Rate as assessed by an IRC according to the 2014 International Working Group (IWG) Lugano Criteria (Cheson, 2014). | Start of treatment to 21 months | CR rate per IRC according to the 2014 IWG Lugano criteria (Cheson, 2014) |
Countries
United States
Outcome results
None listed